Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Completed
LEO Pharma
Phase 2
The purpose of this research trial was to test different strengths of a new trial medication,
delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib
cream affects chronic hand eczema. This was judged by a range of assessments that rate the
severity and extent of chronic hand eczema and its symptoms, as well as general health status
and quality of life.
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
Completed
LEO Pharma
Phase 2
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group
trial. The trial is designed to establish a dose-response signal and investigate the efficacy
and safety of delgocitinib cream in the treatment of adult subjects with mild to severe
atopic dermatitis (AD).
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
Completed
LEO Pharma
Phase 1
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical
delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years
and above) with atopic dermatitis.
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Terminated
LEO Pharma
Phase 2
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase
2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream
in the treatment of adult subjects with discoid lupus erythematosus (DLE).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
